Evidence map›Paper›PMID 34194376›Full record

ArticleFrontiers in psychology2021

Anxiety Impacts Consent Capacity to Treatment in Alzheimer's Disease.

Yuka Kato, Teruyuki Matsuoka, Yoko Eguchi, Kiyoko Iiboshi, Hiroyuki Koumi, Kaeko Nakamura, Kayoko Okabe, Shutaro Nakaaki, Toshiaki A Furukawa, Masaru Mimura and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Yuka KatoDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Teruyuki MatsuokaDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoko EguchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Kiyoko IiboshiDepartment of Clinical Psychology, Faculty of Human Relations, Shigakukan University, Kagoshima, Japan.
Hiroyuki KoumiDepartment of Clinical Psychology, Faculty of Social Welfare, Hanazono University, Kyoto, Japan.
Kaeko NakamuraDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kayoko OkabeDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shutaro NakaakiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Toshiaki A FurukawaDepartment of Health Promotion and Human Behavior, Kyoto University School of Public Health, Kyoto, Japan.
Masaru MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Jin NarumotoDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kyoto Prefectural University of Medicine · JPKeio University · JPHanazono University · JPKyoto University · JPNagoya City University · JPShigakukan University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to clarify how behavioral and psychological symptoms of dementia (BPSD) and cognitive function affect the decision-making capacity of persons with Alzheimer's disease (AD) in a real informed consent situation about anti-dementia drug prescriptions. The participants were 76 patients with AD. We used the MacArthur Competence Assessment Tool to assess the capacity for consent to treatment (MacCAT-T). We simultaneously used the Mini-Mental State Examination, Executive Interview, Executive Clock Drawing Task, Logical Memory I of the Wechsler Memory Scale-Revised (LM I), LM II, and Neuropsychiatric Inventory (NPI) to assess cognitive function and psychiatric symptoms. We calculated the correlations between the MacCAT-T scores and the demographic, neuropsychological, and psychiatric variables. Once the univariable correlations were determined, we performed simple linear regression analyses to examine if the regression equations were significant. In the final analyses, we incorporated significant variables into stepwise multiple linear regression analyses to determine the most significant predictors of mental capacity. Age (β = -0.34), anxiety (β = -0.27), and LM I (β = 0.26) were significant predictors of "understanding" (adjusted

Indexed as

Alzheimer's diseasebehavioral and psychological symptoms of dementiacapacity to consent to treatmentcognitive functiondecision makingMacArthur Competence Assessment Tool

Identifiers

PMID34194376
PMCPMC8236526
OpenAlexW3167341304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.